PD-L1 expression determination defines eligibility for treatment with pembrolizumab in patients with advanced non-small cell lung cancer (NSCLC). This study was designed to better define which value across core biopsies from the same case more closely reflects the PD-L1 expression status on whole sections and how many biopsies are needed for confident classification of tumors in terms of PD-L1 expression.

PD-L1 expression heterogeneity in non-small cell lung cancer: defining criteria for harmonization between biopsies and whole sections

Munari, E
;
Zamboni, G;Brunelli, M;Martignoni, G;Moretta, F;
2018

Abstract

PD-L1 expression determination defines eligibility for treatment with pembrolizumab in patients with advanced non-small cell lung cancer (NSCLC). This study was designed to better define which value across core biopsies from the same case more closely reflects the PD-L1 expression status on whole sections and how many biopsies are needed for confident classification of tumors in terms of PD-L1 expression.
PD-L1; biopsies; cancer; heterogeneity; lung
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/979583
Citazioni
  • ???jsp.display-item.citation.pmc??? 59
  • Scopus 111
  • ???jsp.display-item.citation.isi??? 108
social impact